NEW YORK (GenomeWeb) – The UK's Horizon Discovery Group and Fulcrum Therapeutics have announced a collaboration to use CRISPR/Cas9-based screening to identify drug targets in genetic diseases.

Under the terms of the agreement, Cambridge, Massachusetts-based Fulcrum will use Horizon's CRISPR screening platform to find targets for regulating gene expression in diseases with no current treatment options. The collaboration will last approximately six months and will be done under a full-time equivalent plus consumables model.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.